Ivermectin for COVID: What 8000+ Patients Trail Actually Showed

During the COVID-19 pandemic, few topics created more confusion and emotional debate than ivermectin. Many people felt frustrated, conflicted, and unsure whom to trust—and that reaction was completely understandable. As a primary care physician who managed a COVID floor single-handedly for 11 months, I personally experienced these debates and had countless discussions with specialists across disciplines. For a long time, the confusion around ivermectin was not clearly settled. In this video, I explain: Why early laboratory (Petri dish) studies showed promise Why those doses were not achievable or safe in humans How social media amplified misinformation What early observational studies showed—and their limitations Why large, well-designed clinical trials were necessary Two major studies are discussed: Pilot laboratory studies conducted outside the U.S. The large PRINCIPLE trial in the UK, involving over 8,000 patients Across all key clinical endpoints—prevention of infection, reduction in severity, hospitalization, mortality, and long COVID prevention—ivermectin did not demonstrate benefit at safe human doses. I also address: Why high doses would cause serious neurological and metabolic complications How modern research tools, including artificial intelligence, have improved drug development Why the medical community continued investigating ivermectin despite public disappointment Finally, I share updates on ongoing ivermectin research in cancer, including breast and colon cancer trials in Florida. As of now, no data has been released, but I will continue to report new evidence as it becomes available. My goal is not to dismiss concerns, but to present transparent, evidence-based information so patients can make informed decisions.